Edrecolomab
Alternative Names: 1083 17-1A; 17-1A; Adjuqual; C-1; CO17-1A; M-17-1A; Monoclonal antibody 17-1A; PanorexLatest Information Update: 24 Oct 2021
At a glance
- Originator Centocor
- Developer Ajinomoto; Centocor
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Epithelial cell adhesion molecule inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Market Withdrawal Colorectal cancer
- No development reported Adenocarcinoma
- Discontinued Pancreatic cancer
Most Recent Events
- 20 Feb 2006 Discontinued - Phase-II for Colorectal cancer in Japan (IV-infusion)
- 20 Feb 2006 No development reported - Clinical-Phase-Unknown for Adenocarcinoma in USA (IV-infusion)
- 07 Oct 2003 Clinical trials in Adenocarcinoma in USA (IV-infusion)